Cardioprotective effects of dapagliflozin against doxorubicin-induced cardiotoxicity in breast cancer patients with type 2 diabetes: a prospective study.

BMC Cancer · 2026 · PMC12983706 · PMID 41654775

Europe PMC DOI

hedged sentence

0.1570

closest p · 3.1× alpha

0.1570

boldest claim

The sentences

showed a trendp = 0.157not close (p > 0.1)

Although LVEF showed a trend toward improvement in the dapagliflozin group, the difference was not statistically significant ( p = 0.157) (Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.